Portal de investigación
HDAC5 Inhibitors as a Potential Treatment in Breast Cancer Affecting Very Young Women
Fecha de publicación:
Fecha Ahead of Print:
Autores de INCLIVA
Participantes ajenos a INCLIVA
- Albanell, M
- Ferrer, A
- Nacher, M
Grupos y Plataformas de I+D+i
Abstract
Background: Breast cancer in very young women (BCVY) defined as <35 years old, presents with different molecular biology than in older patients. High HDAC5 expression has been associated with poor prognosis in breast cancer (BC) tissue. We aimed to analyze HDAC5 expression in BCVY and older patients and their correlation with clinical features, also studying the potential of HDAC5 inhibition in BC cell lines. Methods: HDAC5 expression in 60 BCVY and 47 older cases were analyzed by qRT-PCR and correlated with clinical data. The effect of the HDAC5 inhibitor, LMK-235, was analyzed in BC cell lines from older and young patients. We performed time and dose dependence viability, migration, proliferation, and apoptosis assays. Results: Our results correlate higher HDAC5 expression with worse prognosis in BCVY. However, we observed no differences between HDAC5 expression and pathological features. Our results showed greatly reduced progression in BCVY cell lines and also in all triple negative subtypes when cell lines were treated with LMK-235. Conclusions: In BCVY, we found higher expression of HDAC5. Overexpression of HDAC5 in BCVY correlates with lower survival rates. LMK-235 could be a potential treatment in BCVY.
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/)
Datos de la publicación
- ISSN/ISSNe:
- 2072-6694, 2072-6694
- Tipo:
- Article
- Páginas:
- -
- PubMed:
- 32050699
Cancers MDPI
Citas Recibidas en Web of Science: 15
Documentos
Filiaciones
Keywords
- breast cancer; young women; histone deacetylase; HDAC5 inhibitors; LMK-235
Financiación
Proyectos y Estudios Clínicos
Análisis de la desregulación transcriptómica en tejido tumoral de mujeres jóvenes con cáncer de mama e implicaciones funcionales.
Investigador Principal: GLORIA RIBAS DESPUIG
PI13/00606 . INSTITUTO SALUD CARLOS III . 2014
CONTRATOS MIGUEL SERVET TIPO II
Investigador Principal: GLORIA RIBAS DESPUIG
CPII14/00013 . INSTITUTO SALUD CARLOS III . 2015
Análisis de desregulación de microRNAs en lineas de cáncer de mama y estudios comparativo del cáncer de mama en mujeres jóvenes y mujeres mayores.
Investigador Principal: SARA OLTRA SANCHIS
2014/202 . MINISTERIO EDUCACION, CULTURA Y DEPORTE
INCORPORACIÓN DE NUEVAS ÁREAS TEMÁTICAS Y NUEVOS GRUPOS AL CONSORCIO CIBER
Investigador Principal: ANA LLUCH HERNÁNDEZ
CB16/12/00481 . INSTITUTO SALUD CARLOS III
INCORPORACIÓN DE NUEVAS ÁREAS TEMÁTICAS Y NUEVOS GRUPOS AL CONSORCIO CIBER
Investigador Principal: ANDRÉS CERVANTES RUIPEREZ
CB16/12/00473 . INSTITUTO SALUD CARLOS III
Cita
Oltra SS,Cejalvo JM,Tormo E,Albanell M,Ferrer A,Nacher M,Bermejo B,Hernando C,Chirivella I,Alonso E,Burgues O,Pena M,Eroles P,Lluch A,Ribas G,Martinez MT. HDAC5 Inhibitors as a Potential Treatment in Breast Cancer Affecting Very Young Women. Cancers. 2020. 12. (2):412. IF:6,639. (1).
HDAC5 Inhibitors as a Potential Treatment in Breast Cancer Affecting Very Young Women. Oltra SS, Cejalvo JM, Tormo E, Albanell M, Ferrer A, Nacher M, Bermejo B et al. Cancers. 2020 febrero 01. 12 (2):DOI:10.3390/cancers12020412. PMID:32050699.
